The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.
News|Articles|October 31, 2025
Pharmaceutical Executive Presents: Most Favored Nation Order - How Trump Is Disrupting Pharma
Author(s)PharmExec Staff
Listen
0:00 / 0:00
Key Takeaways
- The MFN model, DTC channels, and tariffs are set to transform drug market dynamics, affecting key stakeholders like payers and manufacturers.
- The webinar will evaluate if MFN is a sustainable reform or merely a political issue, impacting future healthcare policies.
Join us for a premium webinar on November 4, 2025!
Advertisement
With Most Favored Nation (MFN) and the emergence of the direct-to-consumer (DTC) model and potential tariffs, traditional roles of payers, pharmacy benefit managers, manufacturers, and 340B hospitals would be fundamentally reshaped.
Exploring the Impacts of MFN, Tariffs and DTC on Drug Markets
On November 4, this exclusive webinar will cut through the political noise and provide a critical, operational analysis of these seismic shifts. We will explore whether MFN is a foundation for permanent reform or simply a political flashpoint, how the proposed mandatory payment models GLOBE and GUARD fit into the future, and what the real-world impact of tariffs and DTC channels will be.
Advertisement
Related to this article
Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring remains a key consideration.
What North American and APAC sponsors need to know about EU Joint Clinical Assessment — and why EMA approval doesn't guarantee reimbursement.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
The Unmet Needs That Will Define the Next Generation of GLP 1s: Q&A with Dr. Bo Liang
3
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
4
Viatris Acquires Pacira BioSciences for $1.65 Billion
5